The drug currently approved for chronic kidney disease (CKD) associated with type 2 diabetes, may benefit a much broader group of patients than previously recognized
POSEIDON is among the largest global datasets to quantify this residual inflammatory burden
Nearly one in five women worldwide are now living with obesity
Consensus calls for nationwide adoption of potassium-enriched salt to reduce cardiovascular disease risk
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
